Logo

Pronota, Molecuence Partner on Stroke Biomarker Deal

Feb 22, 2011

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German biomarker firm Pronota today announced a deal with Molecuence for the discovery and validation of stroke biomarkers.

Pronota will use its MASStermind protein biomarker platform for the discovery stage of the deal, and its MASSterclass technology for the verification work.

Financial and other terms of the deal were not disclosed.

Molecuence, headquartered in Yokohama, Japan, is a wholly owned subsidiary of Mitsubishi Chemical and develops disease biomarkers.

Filed under

Business News
Proteomics & Protein Research
Cardiovascular Disease
Biomarker Discovery & Validation
codevelopment agreement
stroke
proteomics
protein biomarkers
Pronota
Breaking News
The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.